PLx Pharma Inc. to Discuss 2021 Fourth Quarter Financial Results on March 11, 2022 Conference Call and Provide Business Update
February 22 2022 - 3:30PM
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a
commercial-stage drug delivery platform technology company focused
on its clinically-validated and patent-protected PLxGuard™ that has
the potential to improve the absorption of many drugs currently on
the market and to reduce the risk of stomach injury associated with
certain drugs. The Company, with its lead products VAZALORE 81 mg
and VAZALORE 325 mg liquid-filled aspirin capsules (referred to
together as “VAZALORE®”), today announced that it will release its
2021 fourth quarter financial results before the opening of the
U.S. financial markets on Friday, March 11, 2022. Company
executives will host a conference call at 8:30am ET that day with
institutional investors and analysts to provide an overview of PLx
Pharma’s performance for the quarter, along with a business update.
2021 Fourth Quarter Conference Call
Date |
Friday, March 11, 2022 |
Time |
8:30
a.m. ET |
Toll free (U.S.) |
(866)
394-2901 |
International |
(616)
548-5567 |
Conference ID |
2664996 |
Webcast (live and replay) |
https://ir.plxpharma.com/investor-relations |
A replay of the conference call will be
available for two weeks after the call's completion by dialing
(855) 859-2056 (U.S.) or (404) 537-3406 (International). The
conference ID for the replay is 2664996. The archived webcast will
be available via PLx Pharma’s investor relations website for 30
days after the call.
About VAZALORE VAZALORE is an FDA-approved
liquid-filled aspirin capsule, available in 81 mg and 325 mg doses.
VAZALORE delivers aspirin differently from plain and enteric coated
aspirin products. The special complex inside the capsule is
designed for targeted release of aspirin, limiting its direct
contact with the stomach. VAZALORE delivers fast, reliable
absorption for pain relief plus the lifesaving benefits of aspirin.
To learn more about VAZALORE, please visit www.vazalore.com.
About PLx Pharma Inc. PLx Pharma Inc. is a
commercial-stage drug delivery platform technology company focused
on improving how and where active pharmaceutical ingredients (APIs)
are absorbed in the gastrointestinal (GI) tract via its clinically
validated and patent protected PLxGuard™ technology. PLx believes
this platform has the potential to improve the absorption of many
drugs currently on the market or in development, and to reduce the
risk of stomach injury associated with certain drugs. To learn more
about PLx Pharma Inc. and its pipeline, please visit
www.plxpharma.com.
Contacts:Janet M. BarthVice President, Investor
Relations & Corporate Communications, PLx Pharma Inc.(973)
409-6542IR@PLxPharma.com
Lisa M. WilsonFounder & President, In-Site
Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jun 2024 to Jul 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jul 2023 to Jul 2024